Benzinga | Apr 15, 2021 08:07AM EDT

Galecto Highlights Publication Discussing Galectin-3 In Gastric Cancer Journal

Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the publication of a paper in Gastric Cancer, a joint official peer-reviewed journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, demonstrating the key role galectin-3 plays in gastric cancer.

The paper, entitled "Crosstalk between WNT and STAT3 is mediated by galectin3 in tumor progression", outlines how galectin-3 promotes cancer cell growth through the well-established STAT3-WNT pathway. This paper adds to the growing literature indicating a linkage between high levels of galectin-3 in the tumor micro-environment of several cancers, promoting cancer growth, cancer spread and leading to worse prognosis.